Researchers at Yale School of Medicine have discovered that as brain cancers become resistant to treatment, they develop a variety of mutations that differ by cancer subtype. The finding, published in study, could lead to more targeted treatments and move clinicians away from one-size-fits-all approaches toward personalized therapies.
The team focused on oligodendrogliomas and astrocytomas, common types of gliomas. They found that as these cancers become more aggressive, they develop radically different mutations. For years, scientists assumed that recurrence occurred because surgery and other treatments failed to eliminate all cancerous tissue, allowing residual cells to regrow. Why the subsequent tumors are more aggressive, however, remained unclear.
To investigate, the researchers obtained paired tissue samples from approximately 180 patients worldwide. The first sample was taken at initial diagnosis, and the second when the cancer recurred. By analyzing DNA from both sets, the team compared mutations before and after recurrence. They found that the two sets differed radically, and the differences tended to be specific to the glioma subtype. Astrocytomas developed DNA copy-number changes involving deletions or extra copies of entire genome sections, while oligodendrogliomas developed many single-point mutations in cancer genes. Although both cancers looked similar phenotypically, they differed markedly at the DNA level.
This suggests that treatment approaches should focus more on the DNA of the cancers rather than targeting the phenotype when selecting therapies. In this way, treatment resistance could be avoided if patients are monitored for DNA mutations and treatment is adjusted proactively to address those changes.
The big question researchers now pose to the scientific community is whether those mutations can be predicted and acted upon before they occur, so that brain cancer patients can survive much longer than they currently do. That is a question cancer therapy developers like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are likely to ponder as they conduct R&D programs aimed at transforming how brain cancers are treated. The challenge adds to existing hurdles, such as crossing the blood-brain barrier that prevents most treatments from reaching the brain.
The findings underscore the need for dynamic treatment strategies that evolve with the tumor’s genetic profile. If validated in further studies, DNA-guided monitoring could become a cornerstone of precision neuro-oncology, allowing clinicians to stay one step ahead of resistance and improve outcomes for patients with these devastating cancers.
The study was disseminated by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution.
